- Home
- KBDC vs IMNM Comparison
KBDC vs IMNM Comparison
Compare KBDC & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KBDC
- IMNM
- Stock Information
- Founded
- KBDC 2021
- IMNM 2006
- Country
- KBDC United States
- IMNM United States
- Employees
- KBDC N/A
- IMNM N/A
- Industry
- KBDC
- IMNM Medicinal Chemicals and Botanical Products
- Sector
- KBDC
- IMNM Health Care
- Exchange
- KBDC Nasdaq
- IMNM Nasdaq
- Market Cap
- KBDC 1.1B
- IMNM 987.1M
- IPO Year
- KBDC N/A
- IMNM 2020
- Fundamental
- Price
- KBDC $13.58
- IMNM $12.38
- Analyst Decision
- KBDC Buy
- IMNM Strong Buy
- Analyst Count
- KBDC 4
- IMNM 9
- Target Price
- KBDC $16.50
- IMNM $24.89
- AVG Volume (30 Days)
- KBDC 419.8K
- IMNM 1.9M
- Earning Date
- KBDC 11-12-2025
- IMNM 11-12-2025
- Dividend Yield
- KBDC 14.00%
- IMNM N/A
- EPS Growth
- KBDC N/A
- IMNM N/A
- EPS
- KBDC N/A
- IMNM N/A
- Revenue
- KBDC N/A
- IMNM $12,589,000.00
- Revenue This Year
- KBDC $193.84
- IMNM N/A
- Revenue Next Year
- KBDC $7.09
- IMNM $154.70
- P/E Ratio
- KBDC N/A
- IMNM N/A
- Revenue Growth
- KBDC N/A
- IMNM 16.74
- 52 Week Low
- KBDC $13.06
- IMNM $5.15
- 52 Week High
- KBDC $17.99
- IMNM $15.13
- Technical
- Relative Strength Index (RSI)
- KBDC 32.06
- IMNM 63.97
- Support Level
- KBDC $13.08
- IMNM $11.25
- Resistance Level
- KBDC $13.97
- IMNM $12.00
- Average True Range (ATR)
- KBDC 0.28
- IMNM 0.86
- MACD
- KBDC -0.05
- IMNM 0.24
- Stochastic Oscillator
- KBDC 35.37
- IMNM 95.34
About KBDC Kayne Anderson BDC Inc. Common Stock
Kayne Anderson BDC Inc is an externally managed, closed-end, non-diversified management investment company that has elected to be regulated as a business development company that invests primarily in first-lien senior secured loans, with a secondary focus on unitranche and split-lien loans to middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation primarily through debt investments in middle-market companies.
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.